UY31569A1 - Vacunas contra la malaria - Google Patents

Vacunas contra la malaria

Info

Publication number
UY31569A1
UY31569A1 UY31569A UY31569A UY31569A1 UY 31569 A1 UY31569 A1 UY 31569A1 UY 31569 A UY31569 A UY 31569A UY 31569 A UY31569 A UY 31569A UY 31569 A1 UY31569 A1 UY 31569A1
Authority
UY
Uruguay
Prior art keywords
antigen
component
rts
unbound
immunogenic particle
Prior art date
Application number
UY31569A
Other languages
English (en)
Inventor
Florence Emilie Jeanne Francoise Wauters
Dominique Lemoine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40584700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31569(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31569A1 publication Critical patent/UY31569A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invencion se refiere a un componente para una vacuna contra la malaria que comprende: a) una partícula inmunogena RTS, S y/o b) una partícula inmunogena que se deriva de la proteína CS de una o más cepas de P. vivax y el antígeno S de la Hepatitis B y opcionalmente el antígeno S sin fusionar, o c) una partícula inmunogena que comprende RTS, CSV-S y opcionalmente el antígeno S sin fusionar, y d) un agente estabilizante que comprende un agente estabilizante con al menos un grupo funcional tiol, o sus mezclas. También se describen procedimientos para preparar el componente, su uso en medicina, en particular en la prevencion de infecciones de malaria, composiciones/vacunas que contienen el componente y su uso, en particular en terapia.
UY31569A 2007-12-21 2008-12-19 Vacunas contra la malaria UY31569A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1576207P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
UY31569A1 true UY31569A1 (es) 2009-08-03

Family

ID=40584700

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31569A UY31569A1 (es) 2007-12-21 2008-12-19 Vacunas contra la malaria

Country Status (22)

Country Link
US (1) US20100272745A1 (es)
EP (1) EP2234637A2 (es)
JP (1) JP2011507816A (es)
KR (1) KR20100109556A (es)
CN (1) CN102026657A (es)
AP (1) AP2010005296A0 (es)
AR (1) AR071741A1 (es)
AU (1) AU2008339980A1 (es)
BR (1) BRPI0822098A2 (es)
CA (1) CA2708716A1 (es)
CL (1) CL2008003808A1 (es)
CO (1) CO6300963A2 (es)
CR (1) CR11577A (es)
DO (1) DOP2010000189A (es)
IL (1) IL206308A0 (es)
MA (1) MA32030B1 (es)
MX (1) MX2010006984A (es)
PE (1) PE20091528A1 (es)
TW (1) TW200940086A (es)
UY (1) UY31569A1 (es)
WO (1) WO2009080715A2 (es)
ZA (1) ZA201004304B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142278A1 (en) * 2012-03-22 2013-09-26 New York University Plasmodium vivax vaccine compositions
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogs, methods for their production, preparations containing them and their uses
CN105233296B (zh) * 2015-11-24 2018-08-17 江苏省农业科学院 用于鸭病毒性肝炎活疫苗的耐热冻干保护剂及其制备方法和应用
GB201608821D0 (en) 2016-05-19 2016-07-06 Isis Innovation Vaccines
JP7177082B2 (ja) * 2017-04-25 2022-11-22 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
CA3061205A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
CA3075822A1 (en) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
ATE285239T1 (de) * 1996-04-26 2005-01-15 Merck & Co Inc Dna enthaltende impfstoffen
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
WO1999011241A1 (en) * 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
JP2003500456A (ja) * 1999-06-02 2003-01-07 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 角質細胞増殖因子−２製剤
US20070141086A1 (en) * 2003-11-21 2007-06-21 Ohara Michael K Use of antibiotics as vaccine adjuvants
SG183683A1 (en) * 2004-02-02 2012-09-27 Tanox Inc Identification of novel ige epitopes
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1962910A4 (en) * 2005-12-15 2010-03-31 Aeras Global Tb Vaccine Found NEW PRIME BOOST COMBINATION FROM WEAKEN MYCOBACTERIA
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions

Also Published As

Publication number Publication date
MA32030B1 (fr) 2011-01-03
EP2234637A2 (en) 2010-10-06
TW200940086A (en) 2009-10-01
BRPI0822098A2 (pt) 2015-06-30
AR071741A1 (es) 2010-07-14
WO2009080715A3 (en) 2009-11-12
CA2708716A1 (en) 2009-07-02
KR20100109556A (ko) 2010-10-08
DOP2010000189A (es) 2010-08-15
AP2010005296A0 (en) 2010-06-30
PE20091528A1 (es) 2009-10-29
US20100272745A1 (en) 2010-10-28
JP2011507816A (ja) 2011-03-10
IL206308A0 (en) 2010-12-30
CN102026657A (zh) 2011-04-20
WO2009080715A2 (en) 2009-07-02
ZA201004304B (en) 2012-11-28
CO6300963A2 (es) 2011-07-21
CR11577A (es) 2010-09-03
CL2008003808A1 (es) 2011-03-11
AU2008339980A1 (en) 2009-07-02
MX2010006984A (es) 2010-10-25

Similar Documents

Publication Publication Date Title
CO6300963A2 (es) Una vacuna contra la malaria que comprende p. falciparum y p. vivax
BR112018009032A8 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
EA201071087A1 (ru) Моноклональные антитела, способные взаимодействовать с множеством подтипов вируса гриппа а
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
ATE499113T1 (de) Influenzavirus-impfstoffzusammensetzung
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
HRP20140488T1 (hr) Cjepivo protiv influence
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
AR041880A1 (es) Composicion inmunogena
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
AR067087A1 (es) Composicion de vacuna y metodo para elaborarla
AR080111A1 (es) Metodos y composiciones de inmunizacion
AR083361A1 (es) Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
WO2013104995A3 (en) Compositions and methods for treating viral infections
MX2021015972A (es) Vacuna contra la fiebre aftosa.
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
BR112023019301A2 (pt) Formulações de vacina de coronavírus
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
WO2011074006A3 (en) Vaccine composition
CL2023001846A1 (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada